Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus.

Abstract

Diabetic complications in the lower extremities, especially those secondary to diabetic macroangiopathy, have increasingly become a clinical emergency, given the high prevalence and progression of the disease. Until recently, the only approach to treating advanced stage disease was medical therapy and major amputation; however, the advent of revascularization procedures has radically improved the prognosis of patients with critical lower limb ischemia. In this setting, iloprost holds a dual position: as first-choice therapy in patients ineligible for revascularization and as complementary therapy in candidates for surgical or endovascular revascularization.

• Authors: A Piaggesi, V Vallini, E Iacopi, A Tedeschi, A Scatena, C Goretti, L Rizzo
• Journal: Minerva cardioangiologica (Minerva Cardioangiol) Vol. 59 Issue 1 Pg. 101-8 (Feb 2011) ISSN: 0026-4725 [Print] Italy
• PMID: 21285935 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Prostaglandins
• Iloprost

Topics

• Diabetic Angiopathies (drug therapy)
• Drug Interactions
• Humans
• Iloprost (therapeutic use)
• Peripheral Arterial Disease (drug therapy)
• Platelet Aggregation Inhibitors (therapeutic use)
• Prostaglandins (therapeutic use)